GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NuCana PLC (NAS:NCNA) » Definitions » Capital Expenditure

NuCana (NuCana) Capital Expenditure : $-0.59 Mil (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is NuCana Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

NuCana's cash flow for capital expenditures for the three months ended in Dec. 2023 was $-0.12 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.59 Mil.

NuCana Capital Expenditure Historical Data

The historical data trend for NuCana's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NuCana Capital Expenditure Chart

NuCana Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only -1.65 -2.19 -1.42 -0.63 -0.61

NuCana Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.13 -0.19 -0.17 -0.11 -0.12

NuCana Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NuCana (NuCana) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NuCana PLC (NAS:NCNA) » Definitions » Capital Expenditure
Comparable Companies
ABIO CADL PTN SEEL MAIA NRXP ORGS CRIS ALGS VIRX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N04A:Germany
Address
3 Lochside Way, Edinburgh, GBR, EH12 9DT
Website
https://www.nucana.com
NuCana PLC is a biopharmaceutical company focused on improving treatment outcome for cancer patients by ProTide technology. Utilising proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Geographically operates through the region of the United States.